Ashurst advises Atomic Oncology on series seed capital raise

Atomic Oncology has developed a cancer diagnostic technology, ATIx, which provides a predictive test that determines the effectiveness of radiotherapy on cancer patients prior to commencing treatment. The technology is about to undergo final clinical trials. This capital raising is designed to fund the company during the clinical trial period.

Ashurst's team was led by partner Stuart Dullard and counsel Jason Maletic, who were assisted by associate Rebecca Karpin (Corporate Transactions) along with partner Jennie Mansfield and senior associate Mohamad Ardati (Employment) and partner Nina Fitzgerald and associate Ray Cheng (Intellectual Property).